India, May 13 -- TriSalus Life Sciences Inc. (TLSI), an oncology company, on Wednesday reported its first-quarter results and provided various business updates.
Following the release, shares dropped over 47% to a 52-week low on Wednesday.
The company specializes in developing pressure-enabled drug delivery systems (PEDDs) and has received clearance from the U.S. Food and Drug Administration (FDA) for the TriNav Infusion systems in drug delivery to the hepatic arterial infusion of liver tumors.
Q1 2026:
TriSalus saw total revenues of $8.89 million in Q1 2026, a 2.9% decrease from the $9.17 million reported in the same period of 2025. A majority of revenue came from sales of the TriNav system.
Gross margins of 86.2% were achieved, higher...